Long-Term Efficacy and Safety of Anlotinib as a Monotherapy and Combined Therapy for Advanced Sarcoma

References

• Ferrari A, Dirksen U, Bielack S. Sarcomas of soft tissue and bone. Prog Tumor Res. 2016;43:128–141.
   PubMed Web of Science ®Google Scholar
• Tanaka K, Ozaki T. Adjuvant and neoadjuvant chemotherapy for soft tissue sarcomas: JCOG Bone and Soft Tissue Tumor Study Group. Jpn J Clin Oncol. 2021;51(2):180–184. doi:10.1093/jjco/hyaa231
   PubMed Web of Science ®Google Scholar
• Nakata E, Fujiwara T, Kunisada T, et al. Immunotherapy for sarcomas. Jpn J Clin Oncol. 2021;51(4):523–537. doi:10.1093/jjco/hyab005
   PubMed Web of Science ®Google Scholar
• Brownstein JM, DeLaney TF. Malignant soft-tissue sarcomas. Hematol Oncol Clin North Am. 2020;34(1):161–175. doi:10.1016/j.hoc.2019.08.022
   PubMed Web of Science ®Google Scholar
• HaDuong JH, Martin AA, Skapek SX, et al. Sarcomas. Pediatr Clin North Am. 2015;62(1):179–200. doi:10.1016/j.pcl.2014.09.012
   PubMed Web of Science ®Google Scholar
• Detmar M. Tumor angiogenesis. J Investig Dermatol Symp Proc. 2000;5(1):20–23. doi:10.1046/j.1087-0024.2000.00003.x
   PubMedGoogle Scholar
• Shahneh FZ, Baradaran B, Zamani F, et al. Tumor angiogenesis and anti-angiogenic therapies. Hum Antibodies. 2013;22(1–2):15–19. doi:10.3233/HAB-130267
   PubMedGoogle Scholar
• Duffaud F. Role of TKI for metastatic osteogenic sarcoma. Curr Treat Options Oncol. 2020;21(8):65. doi:10.1007/s11864-020-00760-w
   PubMed Web of Science ®Google Scholar
• Du Z, Lovly CM. Mechanisms of receptor tyrosine kinase activation in cancer. Mol Cancer. 2018;17(1):58. doi:10.1186/s12943-018-0782-4
   PubMed Web of Science ®Google Scholar
• Yamaoka T, Kusumoto S, Ando K, et al. Receptor tyrosine kinase-targeted cancer therapy. Int J Mol Sci. 2018;19(11):3491. doi:10.3390/ijms19113491
   PubMed Web of Science ®Google Scholar
• Recine F, De Vita A, Fausti V, et al. Case report: adult NTRK-rearranged spindle cell neoplasm: early tumor shrinkage in a case with bone and visceral metastases treated with targeted therapy. Front Oncol. 2021;11:740676. doi:10.3389/fonc.2021.740676
   PubMed Web of Science ®Google Scholar
• De Vita A, Vanni S, Miserocchi G, et al. A rationale for the activity of bone target therapy and tyrosine kinase inhibitor combination in giant cell tumor of bone and desmoplastic fibroma: translational evidences. Biomedicines. 2022;10(2):372. doi:10.3390/biomedicines10020372
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu P, Shi R. Anlotinib as a molecular targeted therapy for tumors. Oncol Lett. 2020;20(2):1001–1014. doi:10.3892/ol.2020.11685
   PubMed Web of Science ®Google Scholar
• Sun Y, Niu W, Du F, et al. Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors. J Hematol Oncol. 2016;9(1):105. doi:10.1186/s13045-016-0332-8
   PubMed Web of Science ®Google Scholar
• Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res. 2018;24(21):5233–5238. doi:10.1158/1078-0432.CCR-17-3766
   PubMed Web of Science ®Google Scholar
• Liu J, Deng YT, Jiang Y. Switch maintenance therapy with anlotinib after chemotherapy in unresectable or metastatic soft tissue sarcoma: a single-center retrospective study. Invest New Drugs. 2021;39(2):330–336. doi:10.1007/s10637-020-01015-z
   PubMed Web of Science ®Google Scholar
• Su H, Yu C, Ma X, et al. Combined immunotherapy and targeted treatment for primary alveolar soft part sarcoma of the lung: case report and literature review. Invest New Drugs. 2021;39(5):1411–1418. doi:10.1007/s10637-021-01105-6
   PubMed Web of Science ®Google Scholar
• Wang HY, Chu J-F, Zhang P, et al. Safety and efficacy of chemotherapy combined with anlotinib plus anlotinib maintenance in Chinese patients with advanced/metastatic soft tissue sarcoma. Onco Targets Ther. 2020;13:1561–1568. doi:10.2147/OTT.S235349
   PubMed Web of Science ®Google Scholar
• Freites-Martinez A, Santana N, Arias-Santiago S, et al. Using the common terminology Criteria for adverse events (CTCAE - Version 5.0) to evaluate the severity of adverse events of anticancer therapies. Actas Dermosifiliogr. 2021;112(1):90–92. doi:10.1016/j.ad.2019.05.009
   PubMed Web of Science ®Google Scholar
• Skubitz KM, D’Adamo DR. Sarcoma. Mayo Clin Proc. 2007;82(11):1409–1432. doi:10.4065/82.11.1409
   PubMed Web of Science ®Google Scholar
• Ceyssens S, Stroobants S. Sarcoma. Methods Mol Biol. 2011;727:191–203.
   PubMedGoogle Scholar
• Reynoso D, Subbiah V, Trent JC, et al. Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol. 2010;101(4):327–333. doi:10.1002/jso.21481
   PubMed Web of Science ®Google Scholar
• Liu W, Jiang Q, Zhou Y. Advances of systemic treatment for adult soft-tissue sarcoma. Chin Clin Oncol. 2018;7(4):42. doi:10.21037/cco.2018.08.02
   PubMed Web of Science ®Google Scholar
• Claesson-Welsh L, Welsh M. VEGFA and tumour angiogenesis. J Intern Med. 2013;273(2):114–127. doi:10.1111/joim.12019
   PubMed Web of Science ®Google Scholar
• Nguyen DT, Shayahi S. Pazopanib: approval for soft-tissue sarcoma. J Adv Pract Oncol. 2013;4(1):53–57. doi:10.6004/jadpro.2013.4.1.6
   PubMedGoogle Scholar
• van der Graaf WT, Blay J-Y, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled Phase 3 trial. Lancet. 2012;379(9829):1879–1886. doi:10.1016/S0140-6736(12)60651-5
   PubMed Web of Science ®Google Scholar
• Agulnik M, Attia S. Growing role of regorafenib in the treatment of patients with sarcoma. Target Oncol. 2018;13(4):417–422. doi:10.1007/s11523-018-0575-0
   PubMed Web of Science ®Google Scholar
• Li S. Anlotinib: a novel targeted drug for bone and soft tissue sarcoma. Front Oncol. 2021;11:664853. doi:10.3389/fonc.2021.664853
   PubMed Web of Science ®Google Scholar
• Wang G, Sun M, Jiang Y, et al. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma. Int J Cancer. 2019;145(4):979–993. doi:10.1002/ijc.32180
   PubMed Web of Science ®Google Scholar
• Zhu MMT, Shenasa E, Nielsen TO. Sarcomas: immune biomarker expression and checkpoint inhibitor trials. Cancer Treat Rev. 2020;91:102115. doi:10.1016/j.ctrv.2020.102115
   PubMed Web of Science ®Google Scholar
• Hall F, Villalobos V, Wilky B. Future directions in soft tissue sarcoma treatment. Curr Probl Cancer. 2019;43(4):300–307. doi:10.1016/j.currproblcancer.2019.06.004
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu L, Liu L, et al. A phase I study investigation of metabolism, and disposition of [(14)C]-anlotinib after an oral administration in patients with advanced refractory solid tumors. Cancer Chemother Pharmacol. 2020;85(5):907–915. doi:10.1007/s00280-020-04062-8
   PubMed Web of Science ®Google Scholar
• Paoluzzi L, Maki RG, Nguyen DT, Shayahi S. Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma: a review. JAMA Oncol. 2019;5(2):254–260. doi:10.1001/jamaoncol.2018.4490
   PubMed Web of Science ®Google Scholar
• Penel N, Adenis A, Bocci G. Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going? Crit Rev Oncol Hematol. 2012;82(1):40–50. doi:10.1016/j.critrevonc.2011.04.009
   PubMed Web of Science ®Google Scholar
• Mutsaers AJ. Metronomic chemotherapy. Top Companion Anim Med. 2009;24(3):137–143. doi:10.1053/j.tcam.2009.03.004
   PubMed Web of Science ®Google Scholar
• Shao Y, Zhong DS. Histological transformation after acquired resistance to epidermal growth factor tyrosine kinase inhibitors. Int J Clin Oncol. 2018;23(2):235–242. doi:10.1007/s10147-017-1211-1
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Nishimura S, Ito T, et al. Immunohistochemical expression and clinicopathological assessment of PD-1, PD-L1, NY-ESO-1, and MAGE-A4 expression in highly aggressive soft tissue sarcomas. Eur J Histochem. 2022;66(2). doi:10.4081/ejh.2022.3393.
   Web of Science ®Google Scholar
• Hashimoto K, Nishimura S, Ito T, et al. Clinicopathological assessment of cancer/testis antigens NY-ESO-1 and MAGE-A4 in highly aggressive soft tissue sarcomas. Diagnostics. 2022;12(3). doi:10.3390/diagnostics12030733.
   Web of Science ®Google Scholar